TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
RPRX

Royalty Pharma Plc

Healthcare · Biotechnology

56.40$ -0.4% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Cash Flow

Royalty Pharma Plc (RPRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at 686 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Cash Flow RPRX
Line item Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
– – – – – – -3.1 -4.6 -2.0 -2.0 433 337 419 478 471 489 509 566 526 532 470 490 460 575 539 570 1,034 608 574 773 665 658 704 743 596 364 703 827 761 686 2,976
– – – – – – 0.0 0.0 0.0 0.0 6.6 5.7 – – 5.7 5.7 5.8 5.8 5.7 5.7 5.8 5.8 5.7 0.0 0.0 -5.7 0.0 0.0 0.0 0.0 – 4.6 -4.6 – 0.0 1.4 1.3 1.2 1.2 -1.2 2.5
– – – – – – – – – – – – – – – 3.7 0.8 0.8 0.7 0.7 0.5 0.5 0.5 0.5 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.7 0.5 0.5 0.5 91 73 126 122 107 428
– – – – – – 0.4 0.4 0.3 -0.2 -30 184 -63 – 351 -1.4 168 270 19 -473 6.9 6.3 21 9.6 -241 20 32 21 – – – – – – – – – – – – –
– – – – – – – – – – -382 -435 – 499 51 -0.5 -4.9 31 -33 34 -63 46 -40 78 -31 25 -43 38 -37 48 -29 50 -19 52 -64 50 -51 49 835 -1,670 -838
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1,208 0.0 4.0 4.4 99 490 0.0 805 503 181 1,336 172 68 175 1,316 271 602 60 451 1,002 86 747 833 0.0 0.0 0.0 1.1 0.0 0.0 0.0 1.1
– – – – – – – – – – -1,317 -158 -615 -25 -762 -245 -920 -832 -599 126 -846 -552 11 -30 -1,425 415 -559 -63 -451 -1,000 -87 -893 -1,193 -506 504 -312 -958 -848 -520 -187 -2,514
– – – – – – – – – – 198 198 168 175 142 144 55 58 66 73 73 74 82 83 84 84 89 91 90 89 94 95 94 94 95 93 95 94 104 105 399
– – – – – – 1.3 1.0 2.5 – -2.3 -1.9 – – – – -9.0 -1.0 -126 -112 -125 -116 -106 -109 -107 179 -33 -165 -140 -30 0.0 -80 -97 -53 -709 -292 -146 -81 -50 -45 -322
– – – – – – – – – – -74 -74 -74 – 823 -47 -95 1,273 1,273 1,273 1,260 -0.8 – – – -1.3 – – – – – – 0.0 0.0 – – 954 0.0 – – –
0.1 0.1 0.1 0.1 0.1 1.6 2.9 1.0 3.5 3.5 -315 -310 -281 -286 543 1,579 -357 -277 -227 -224 1,034 -198 -221 -228 -230 -266 -210 -347 -1,359 -232 -212 1,157 -326 -258 -941 -508 563 -300 -273 -273 -283
– – – – – – -1.8 -3.6 0.5 -2.0 -1,199 -132 -477 167 252 1,823 -769 -544 -300 433 659 -260 250 317 -1,116 719 265 197 -1,237 -459 366 922 -815 -21 159 -456 307 -320 -32 226 180
– – – – – – – – – – 433 337 419 478 471 489 509 566 526 532 470 490 460 575 539 570 1,034 608 574 773 665 658 704 743 596 364 703 827 761 686 2,976

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?